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Abstract 
The exposure and release of TF is regulated by post-translational modifications of its cytoplasmic 
domain. Here, the potential of Pin1 to interact with the cytoplasmic domain of TF, and the outcome on TF 
function was examined. MDA-MB-231 and transfected-primary endothelial cells were incubated with 
either Pin1 deactivator Juglone, or its control Plumbagin, as well as transfected with Pin1-specific or 
control siRNA. TF release into microvesicles following activation, and also phosphorylation and 
ubiquitination states of cellular-TF were then assessed. Furthermore, the ability of Pin1 to bind wild-type 
and mutant forms of overexpressed TF-tGFP was investigated by co-immunoprecipitation. Additionally, 
the ability of recombinant or cellular Pin1 to bind to peptides of the C-terminus of TF, synthesised in 
different phosphorylation states was examined by binding assays and spectroscopically. Finally, the 
influence of recombinant Pin1 on the ubiquitination and dephosphorylation of the TF-peptides was 
examined. Pre-incubation of Pin1 with Juglone but not Plumbagin, reduced TF release as microvesicles 
and was also achievable following transfection with Pin1-siRNA. This was concurrent with early 
ubiquitination and dephosphorylation of cellular TF at Ser253. Pin1 co-immunoprecipitated with 
overexpressed wild-type TF-tGFP but not Ser258→Ala or Pro259→Ala substituted mutants. Pin1 did 
interact with Ser258-phosphorylated and double-phosphorylated TF-peptides, with the former having 
higher affinity. Finally, recombinant Pin1 was capable of interfering with the ubiquitination and 
dephosphorylation of TF-derived peptides. In conclusion, Pin1 is a fast-acting enzyme which may be 
utilised by cells to protect the phosphorylation state of TF in activated cells prolonging TF activity and 
release, and therefore ensuring adequate haemostasis. 
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1. Introduction 
Precise control of the release of tissue factor (TF) as microvesicle by cells is crucial for 
adequate coagulation, without the risk of thrombosis. Consequently, the regulation of TF release 
by cells is subject to a number of mechanisms that act as positive and negative factors. 
Furthermore, TF appears to have a number of cellular functions, beyond that of initiating the 
coagulation mechanism [1-3]. Regulation of the incorporation of TF into cell derived 
microvesicles and also the termination of this process, entails mechanisms that include multiple 
post-transcriptional modifications of the cytoplasmic domain of TF [3-8]. The phosphorylation 
of TF by protein kinase c at serine 253 occurs following the de-palmitoylation of the cytoplasmic 
domain of TF [8] and permits the recruitment of filamin A which is essential for the 
incorporation of TF into microvesicles [9-11]. In contrast, the delayed phosphorylation of TF at 
serine 258 by p38 [5] appears to eventually lead to dephosphorylation of serine 253 within TF, 
by phosphatase PP2A [4]. Therefore an inescapable remaining question concerns the mechanism 
by which cells gauge the level of TF required/released for appropriate coagulation, and shut 
down the release process. Interestingly, double-phosphorylation of TF creates a suitable 
ubiquitination site within the cytoplasmic domain of TF which in turn may promote TF 
dephosphorylation [6]. Furthermore, the phosphorylation of serine 258 produces a 
phosphoserine-proline motif (termed an MPM-2 motif) which suggest the involvement of the 
enzyme peptidy-prolyl trans/cis isomerase 1 (Pin1) [12-14]. This enzyme is known to alter the 
structure of a number of proteins with a similar motif resulting in wide-ranging outcomes [14-17] 
including alteration in susceptibility of the target protein to dephosphorylation [16-19], 
ubiquitination [19,21] as well as the function and stability of the proteins [16,22-24]. In this 
study we examine the hypothesis that Pin1 is a crucial moderator which acts to regulate the 
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termination of the release of TF, through a mechanism that is dependent on the level of TF being 
released and therefore, the level of cellular activation. 
 
2. Materials and Methods 
2.1. Cell culture and transfection, microvesicle preparation and measurement of TF 
mRNA, antigen and activity 
MDA-MB-231 cell line (ATCC, Teddington, UK) was cultured in DMEM containing 10% 
(v/v) foetal calf serum (FCS). Human coronary artery endothelial cells (HCAEC) were 
purchased and cultured in MV media containing 5% (v/v) FCS and growth supplements 
(PromoCell, Heidelberg, Germany). MDA-MB-231 cells and HCAEC (2×105) were transfected 
with 1 µg of pCMV6-Ac-TF-tGFP plasmid DNA (OriGene, Rockville, USA) or alternatively, 
mutant forms of the plasmid containing alanine-substitutions at position 258 (Ser→Ala) and 
position 259 (Pro→Ala) as previously described [4]. Transfection of the cells were carried out 
using Lipofectin (Invitrogen, Paisley, UK) as previously described in order to express the various 
types of TF [4]. Cells (2×105) were seeded out in 6-well plates and pre-adapted (1 h) to 
respective serum-free medium prior to experiments [4,9]. To induce microvesicle release, the 
cells were stimulated with protease activated receptor 2-activating peptide (PAR2-AP); SLIGRL; 
(20 µM). The released microvesicles were then isolated from conditioned media, resuspended in 
phosphate-buffered saline (PBS) and assessed according to published procedures [25]. The 
microvesicles were quantified using the functional assay Zymuphen MP assay kit (Hyphen 
BioMed/Quadratech Ltd, Epsom, UK) and the microvesicle density determined from the 
standards provided by the kit. Microvesicle-associated TF antigen and activity were measured 
using a TF-EIA kit and thrombin-generation assay, respectively [4,26,27]. Cell numbers in the 
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samples were determined by staining with crystal violet as previously described [28,29]. In some 
experiments the cells were pre-incubated with Juglone (5-hydroxy-1,4-naphthalenedione) (0-60 
mM; Sigma Chemical Co. Ltd, Poole, UK) or Plumbagin (5-hydroxy-2-methyl-1,4-
naphthoquinone) (0-60 mM; Sigma) prior to activation. Other samples of cells were transfected 
with a specific set of Silencer®-siRNA (4 nM; Life Technologies, Paisley, UK) to suppress the 
expression of Pin1, or transfected with a comparable set of control siRNA (4 nM; Life 
Technologies) prior to activation. The concentration of the Pin1-siRNA was optimised and the 
downregulation in the expression of Pin1 confirmed prior to the experiments by ELISA and 
western blot analysis (Supplementary Fig 1). The expression of TF mRNA and protein in the 
cells as well as cell surface TF were monitored using RT-PCR, TF-EIA and flow cytometry as 
previously described [9,26]. 
2.2. Immunoprecipitation of TF protein 
TF protein was immunoprecipitated from cell lysates using mouse or rabbit anti-human TF 
antibodies depending on the target analysis. Therefore, a rabbit anti-human antibody (FL295) 
(Santa Cruz Technology, Heidelberg, Germany) (4 µg per sample) was employed when the 
samples were to be subsequently examined using anti-mouse antibodies by western blot. 
Conversely a mouse anti-TF antibody (10H10) (Santa Cruz) (4 µg per sample) was used for 
immunoprecipitation when the western blot analysis involved anti-rabbit antibody. In some 
experiments using transfected cells, TF-tGFP was immunoprecipitated using an with anti-tGFP-
magnetic beads (clone 2H8) (25 μl) as previously outlined [6]. To ensure specificity, appropriate 
IgG isotypes (Cell Signalling Technology) were also included at identical concentrations 
alongside, as well as additional controls without any antibody. All samples were incubated at 
4°C overnight with gentle shaking. Pureproteome protein A-magnetic beads (10 µl) (Merck-
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Millipore) was added to all samples and controls and incubated at 4°C for 90 min with shaking. 
The samples were then placed in a magnetic stand and the supernatant removed, washed five 
times with PBST (1 ml) and the samples denatured in SDS-PAGE loading buffer (70 µl) 
(Sigma). 
2.3. Western blot analysis 
Electrophoresis was carried out on a 12% (w/v) denaturing-polyacrylamide gel and the 
protein bands were transferred onto nitrocellulose membranes and blocked with TBST (10 mM 
Tris-HCl pH 7.4, 150 mM NaCl, 0.05% Tween-20). Western blot analysis of the samples was 
carried out to detect TF using FL295 antibody (when IP was carried out using 10H10 antibody) 
diluted 1:4000 (v/v) in TBST. Alternatively, 10H10 and/or HTF1 (eBioscience/ Thermo 
Scientific, Warrington, UK) antibodies were used when IP was with FL295 antibody (diluted 
1:2000 and 1:4000 (v/v) in TBST respectively). The membranes were then washed with TBST 
and probed with goat anti-rabbit, or goat anti-mouse alkaline phosphatase-conjugated antibodies 
(Santa Cruz), diluted 1:4000 (v/v) depending on the source of the primary antibody, and 
incubated for 90 min. TF bands were then visualised using the Western Blue stabilised alkaline 
phosphatase-substrate (Promega Corp. Southampton, UK) and recorded. No species cross-
detection between the primary and the secondary antibodies were observed (Supplementary Fig 
2). In addition ubiquitination was detected in samples immunoprecipitated with FL295 antibody, 
using a mouse anti-human mono/poly-ubiquitin (FK2) antibody (Enzo) diluted 1:4000 (v/v), and 
developed as above [6]. Phosphorylation of Ser258 was detected in samples immunoprecipitated 
with 10H10 antibody using a rabbit anti-phosphoserine-TF antibody (Abcam, Cambridge, UK) 
specific for phospho-Ser258, diluted 1:2000 (v/v) in TBST while phosphorylation of Ser253 was 
 7 
detected using a rabbit anti-phospho-PKC-substrate motif antibody (Cell Signalling Technology) 
diluted 1:2000 (v/v) in TBST buffer as previously described [4]. 
2.4. Pin1 binding assay 
Substrate peptides, corresponding to the last 19 amino acids of the cytoplasmic domain of TF 
were synthesised in biotinylated form (Biomatik, Ontario, Canada). In total 4 peptides were 
synthesised in non-phosphorylated, single-phosphorylated and double-phosphorylated forms and 
used as substrates. An additional scrambled peptide (biotin-SWGNVSKLSAPRQGVNKE) was 
also included alongside. The peptides (5 µM final concentration) were diluted to 100 µl with 
PBS and distributed (50 µl per well) in a NeutrAvidin-coated 96-well plate (Thermo Scientific, 
Warrington, UK) and incubated for 2 h at room temperature to allow binding. The procedure was 
based on a variation of a previously described binding assay [30]. The wells were washed four 
times, each time with 300 µl of PBST. HRP-conjugated recombinant Pin1 protein was diluted 
1:500 (v/v) in PBST, added to the wells (100 µl) and incubated for 1 h at room temperature. The 
wells were then washed a further four times and developed with TMB One Solution (100 µl) 
(Promega). Once the colour was developed the reactions were stopped by the addition of 2M 
sulphuric acid (50 µl) and absorptions measured at 450 nm using a plate reader. The 
cocnentrations of Pin1 were determined from a standard curve made using HRP-conjugated 
recombinant Pin1 protein. In addition, the time-course of interaction of Pin1 with the labelled 
penta-peptides, Succ-Glu-Asn-Ser-Pro-Leu-pNitroanilide and Succ-Glu-Asn-phosphoSer-Pro-
Leu-pNitroanilide, was investigated by measuring the alteration in spectroscopic absorption of 
the solution using a procedure based on that described by Janowski et al [31]. Prior to the 
experiments the peptides (0.5 µM) were reconsituted in Tris-HCl buffer at a range of pH values 
ranging between 5.5-9.5. The absorption spectra of the peptide was analysed at 260-360 nm 
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range and the maximal change in the absorption spectrum was determined to be 315 nm (see 
results). The absorption spectrum of the recombinant HRP-conjugated Pin1 was also examined 
which was confimed not to absorb light at 315 nm (not shown). Samples (100 µl) of the peptides 
were in turn placed in a microcuvette, and recombinant HRP-conjugated Pin1 added (10 nM 
final concentration). The change in absorption at 315 nm over time was then monitored. 
2.5. Determination of cellular Pin1 concentrations by ELISA 
The concentrations of Pin1 protein in MDA-MB-231 cells and HCAEC (2×105) were 
determined using a Pin1-ELISA kit (Enzo Life Sciences, Exeter, UK) according to 
manufacturer's instructions. This procedure was also used to confirm the lack of Pin1 protein 
after knock out using siRNA as stated above. 
2.6. Pin1 binding pull-down assay 
A pull-down assay was carried out in a similar procedure to the binding assay with minor 
alterations. The procedure was carried out using cell lysate (100 µl from 2×105 cells) instead of 
recombinant Pin1-HRP and incubated for 1 h at room temperature. Following binding, the wells 
were washed with PBST and probed for Pin1 using the HRP-conjugated detection antibody from 
the Pin1-ELISA kit, as above. The concentrations of Pin1 were determined from a standard curve 
made using recombinant Pin1 protein from the ELISA kit. In similar experiments, the affinity 
purified proteins were dissolved in the electrophoresis sample buffer and analysed by western 
blotting, using a rabbit anti-Pin1 polyclonal antibody (GenTex-Insight Biotechnology Ltd, 
Wembley, UK) diluted 1:2000 (v/v) in TBST. The membranes were then developed using an 
alkaline-phosphatase conjugated goat anti-rabbit IgG secondary antibody, and visualised with 
Western blue substrate as described above. 
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2.7. Phosphatase assay 
The phosphatase assay was carried out as previously described [6], using the biotinylated 
peptides representing the 19 amino acids of the cytoplasmic domain of TF. The peptides (10 µM) 
were diluted in phosphate-free Tris-HCl (50 mM) pH 7.5 (100 µl), adsorbed onto the 
NeutrAvidin 96-well plates and washed fours times with phosphate-free Tris-HCl (300 µl). Each 
reaction (25 µl) was prepared by assembling recombinant phosphatase PP2Aα (0.2 µg) 
(SignalChem/Stratech, Newmarket, UK) in phosphatase reaction buffer (200 mM immidazole 
pH 7.2, 0.1% (w/v) β-mercapthoethanol and 52 ng/ml bovine serum albumin) and MgCl2 (10 
mM). A similar set of samples were prepared but devoid of the enzyme. A positive control was 
prepared as above but containing the peptide KRpTIRR (10 µM) which is recommended as a 
positive control substrate by the phosphatase PP2A manufacturer. A negative control devoid of 
any substrate was also included. The samples were incubated at 37°C for 60 min and aliquots of 
reaction (20 µl) were transferred into a fresh 96-well plate and 150 µl of BioMol (Enzo) added 
and incubated for 30 min. The absorptions were then measured at 630 nm using a plate reader 
and concentrations determined from a phosphate-standard curve. 
2.8. Ubiquitination assay 
Ubiquitination reaction was carried out as before [6], using the E2-Screening kit 
(UBPBio/Caltag Medsystems, Buckingham, UK) and modified as described below to 
accommodate the various studies. The reactions (25 µl total volume) were set up to contain 
substrate peptide (5 µM), Ube1 enzyme (0.1 µM), Ube2D enzyme mix (2 µM), ubiquitin 
monomer (50 µM), ATP (2 mM), glycerol (5% w/v) and reaction buffer (20 mM Tris, pH 7.6, 50 
mM NaCl, 1 mM β-mercapthoethanol and 5 mM MgCl2) and recombinant Mdm2 (0.5 µM) 
(R&D Systems). The reactions were carried out at 37°C for 60 min and analysed as follows. The 
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samples were diluted to 100 µl with PBS and distributed (50 µl per well) in a NeutrAvidin-
coated 96-well plate (Thermo Scientific, Warrington, UK) and incubated for 60 min at room 
temperature. The wells were washed four times with PBST (300 µl) and incubated with HRP-
conjugated anti-human mono/poly-ubiquitin (FK2) antibody (Enzo) diluted 1:500 (v/v) in PBST 
(100 µl). The wells were then washed a further four times and developed with TMB One 
Solution (100 µl) (Promega). Once the colour was developed the reactions were stopped by the 
addition of 2M sulphuric acid (50 µl) and absorptions measured at 450 nm using a plate reader. 
 
3. Results 
Prior to the study, the suppression of Pin1 using the Silencer® siRNA in MDA-MB-231 cells 
was optimised (Supplementary Fig 1). Downregulation of Pin1 by siRNA knockdown, or 
deactivation using Juglone had no influence on TF mRNA or protein levels or cell surface TF 
exposure compared to control siRNA or cells incubated with Plumbagin (Supplementary Fig 3). 
Moreover, the rate of cell proliferation was not significantly altered in cells transfected with Pin1 
siRNA compared to those transfected with control siRNA (Supplementary Fig 4), although Pin1 
is thought to interact with proteins involved in the M-phase of the cell cycle. In addition, the 
duration of incubation with Juglone/Plumbagin was not long enough to influence cell 
proliferation and cell numbers were unchanged. Therefore, these data indicate that other cellular 
alterations arising from Pin1 deactivation or knock-down, were not significant in the present 
studies. 
3.1. Pin1 is required for the prolonged release of TF into microvesicles without affecting 
microvesicle release 
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Deactivation of Pin1 in MDA-MB-231 cells by incubation with Juglone, prior to the 
activation of the cells with PAR2-AP, reduced the release of TF within microvesicles in a 
Juglone-concentration dependent manner (Fig 1A). A similar pattern was observed in transfected 
HCAEC expressing TF-tGFP, but with a lower threshold (Fig 1B). In contrast, pre-incubation of 
the cells with the non-inhibiting analogue Plumbagin, or the vehicle DMSO did not alter the 
release of TF in either cell type. Importantly, pre-incubation of cells with Juglone did not alter 
the release of the microvesicles themselves (Fig 1C & 1D). Similarly, suppression of Pin1 
expression in MDA-MB-231 cells and HCAEC using specific siRNA significantly reduced the 
release of TF, while the control siRNA was ineffective (Fig 1E & 1F). Moreover, the suppression 
of Pin1 using siRNA had no influence on microvesicle release (Fig 1G & 1H). 
3.2. Pin1 protects the phosphorylation state of Ser253 in cells and prevents the 
ubiquitination of TF 
The expression of Pin1 was suppressed in MDA-MB-231 cells using siRNA knockdown as 
above. A set of cells were transfected with control siRNA in parallel. The cells were activated 
using PAR2-AP and samples were collected at 15, 30 and 45 min. The TF was 
immunoprecipitated from the cell lysates and examined for TF phosphorylation at Ser253 and 
Ser258 by western blot analysis with maximal differences observed at 30 min (Fig 2A). It must 
be noted that due to the procedure used, the immunoprecipitated TF antigen is a purified sample 
and may not be used to compare the amount of cellular TF in these samples. Also, since no 
housekeeping control is available, all comparisons were made with respect to the 
immunoprecipitated TF antigen levels. In the absence of Pin1 the phosphorylation of Ser253 was 
largely diminished at any of the time points assessed while it was clearly detectable in the control 
cells at 15 and 30 min (Fig 2B). Interestingly, the phosphorylation state of Ser258 was not 
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significantly altered following suppression of Pin1 (Fig 2C). Furthermore, treatment of cells with 
Juglone but not Plumbagin also protected the phosphorylation state of Ser253 without altering 
the state of Ser258 (Supplementary Fig 5). No TF phosphorylation was detected in any of the 
samples or control prior to PAR2 activation (not shown). Similar studies using HCAEC 
produced only small amounts of TF probably due to double transfection procedure 
(Supplementary Fig 6) and therefore were not pursued further. 
3.3. Pin1 preferably interacts with Ser258-phosphorylated TF but also with double-
phosphorylated form 
MDA-MB-231 cells were transfected to express the wild type-TF-tGFP, or alternatively with 
alanine-substitution at Ser258 or Pro259. The cell lysates were used to immunoprecipitate the 
expressed proteins using anti-tGFP-magnetic beads (clone 2H8). An additional sample was 
immunoprecipitated using anti-TF from the lysate of cells expressing wild type-TF-tGFP, and 
used for comparison. Examination of the immunoprecipitated products by western blotting, using 
an anti-Pin1 polyclonal antibody, indicated the co-purification of Pin1 with wild-type TF and the 
wild-type TF-tGFP (Fig 3A). In contrast, very low levels of Pin1 were detected in the sample 
containing the TF-tGFP with Pro259→Ala-substitution (<20% of the wild-type TF), and in the 
sample with TF-tGFP Ser258→Ala-substitution (<10% of the wild-type TF) (Fig 3B). Similar 
studies using HCAEC produced only small amounts of TF as stated above, and therefore were 
not pursued further. In order to determine the preferred form of TF as a substrate for Pin1, four 
peptides corresponding to the 19 amino acids of the C-terminus of TF were synthesised in 
unphosphorylated, Ser253-phosphoryalted, Ser258-phosphorylated and double-phosphorylated. 
A scrambled peptide (biotin-SWGNVSKLSAPRQGVNKE) was included. The peptide were 
prepared with a biotin tag and adsorbed in NeutrAvidin 96-well plates. The plates were then 
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incubated with a range of concentrations of recombinant HRP-conjugated active Pin1, washed 
and the interactions detected using TMB substrate. HRP-Pin1 appeared to interact with Ser258-
phosphorylated peptide preferentially and to a lesser extent with the double-phosphorylated 
peptide (Fig 3C). Interestingly, the interaction with Ser253-phosphorylated peptide was the least 
favourable. An attempt was made to determine the relative dissociation constants (Fig 3D & 
Table 1). However since Pin1 may interact with peptides differently to the TF molecule, these 
are relative values only, and are therefore likely to be dissimilar to the real dissociation constants 
values between Pin1 and TF, or the peptide motifs reported previously [32]. Similarly, 
incubation of the NeutrAvidin-anchored peptides with cell lysate resulted in the interaction of 
cellular Pin1 with the peptides (Fig 3E) which also mirrored the pattern observed using the 
recombinant Pin1. Interestingly, while the values were much lower than those observed with 
HRP-conjugated recombinant Pin1, the differences between the four peptides were more 
discernable when examining cellular Pin1 by pull down assay. Analysis of purified proteins by 
western blot showed the presence of Pin1 as faint bands with a molecular weight of around 18 
kDa (Fig 3F) however, the quantity of the purified Pin1 was far too small to permit any 
meaningful quantification using this technique. In an attempt to determine the speed of the 
reaction, smaller penta-peptides corresponding to residues 256-260 (encompassing Ser258 but 
not Ser253) were synthesised with p-nitroanilide on the C-terminus. This procedure permits the 
measurement of changes in the environment of the nitroanilide by spectroscopic analysis and 
would indicate any interaction between Pin1 and the peptides [31]. However, the procedure is 
only relative and indicative, and therefore no attempt was made to derive further kinetic 
parameters for the interactions. The peptides were synthesised in non-phosphorylated and 
Ser258-phosphorylated format, and the spectra analysed at various pH values. The wavelength of 
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maximal change was determined to be 315 nm for both peptides (Fig 3G). Incubation of the 
Ser258-phosphorylated peptide with Pin1 resulted in rapid change in absorption at 315 nm and 
was slower in the unphosphorylated peptide (Fig 3H). 
3.4. Pin1 can interfere with ubiquitination of TF by ubiquitin ligase complex 
Suppression of Pin1 in MDA-MB-231 cells resulted in the early ubiquitination of TF (Fig 
4A) which was clearly visible at 15 min in the cells devoid of Pin1 but only became significant at 
30 min in the control cells (Fig 4B). This ubiquitination was associated with the activation of the 
cells and was absent in prior to PAR2 activation, in cells devoid of Pin1 (supplementary Fig 7). 
Moreover, the examination of the gel did not show multiple banding or smearing associated with 
poly-ubiquitination (supplementary Fig 8) and is in agreement with our previous study [6]. 
However, the multiple banding pattern of the oligoubiquitinated TF protein was less visible than 
previously reported by us. This was deemed to be as a consequence of the lower number of cells 
used in the experiments, as well as the transient nature of the TF oligoubiquitin chain which was 
short lived in MDA-MB-231 cells [6]. Additionally, due to immunoprecipitation procedure, the 
protein content analysed was a fraction of the cellular TF and not representative of the total 
cellular TF. Again, the amounts of recovered TF from double-transfected HCAEC were too low 
to determine the values reliably and are not presented. Double-phosphorylated TF peptide was 
ubiquitinated by the ubiquitin ligase complex containing Ube2D family of E2 ligases and Mdm2 
as the E3 ligase [6] in the presence and absence of recombinant Pin1. Addition of recombinant 
Pin1 (1-10 nM) to the ubiquitination reaction suppressed the ubiquitination of the TF-peptide in a 
concentration-dependent manner (Fig 4C). However, since the experiment was carried out under 
static conditions i.e. the product is not removed from the reaction, higher concentrations of Pin1 
would result in the increased isomerisation in both directions and were not deemed reliable or 
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examined further. Analysis of the collected microvesicles did not show any ubiquitination of TF 
(not shown). 
3.5. Pin1 can interfere with TF dephosphorylation 
The inclusion of Pin1 into the reaction reduced the ability of recombinant phosphatase 
PP2Aα to release inorganic phosphate from the double-phosphorylated TF peptide (Fig 5A) but 
not the Ser253-phosphorylated peptide (Fig 5B). Replacement of the double-phosphorylated TF 
peptide with a ubiquitinated form liberated a significantly higher amount of inorganic phosphate 
by PP2Aα (Fig 5C) but was reduced in a similar manner to the non-ubiquitinated peptide, in the 
presence of Pin1. Finally, to determine the potential of Pin1 to interfere with TF processing 
within cells, the concentration of Pin1 was measured using an ELISA system. The concentration 
of Pin1 was determined to be 44.8 nM ± 0.5 in MDA-MB-231 cells while the levels present in 
HCAEC was determined to be measured 19.3 nM ± 1.7. 
3.6. Structural analysis of the outcome of Pin1-mediated isomerisation of TF 
Analysis of the NMR structure of the cytoplasmic domain of TF (2CEF) [33] obtained from 
the databank showed that the Lys255 is present at the surface of the protein (Fig 6A) in 9 out of 
the 10 prevelent structures (not included). In one remaining structure, Lys255 is only partially 
covered by the side chain of Asn261. However, since the Asn261 appears exceptionally flexible 
it would not interefer with the head group of Lys255. Importantly, Lys255 appears to form 
hydrogen bonds with the backbone carboxy groups from Asn257, phosphoSer258 and Pro259 
(Fig 6B) and to a lesser extent with the backbone carboxy group of Glu256 (Table 2). These 
interactions appear to anchor the ε-amino group of Lys255 allowing only limited movement 
which was found to be 4.02 Å laterally (across the protein surface), and up to 2.44 Å away from 
the surface of the protein, measured by calculating the greatest relative movemet of the ε-amino 
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group betwen all 10 structures. In addition, the acyl group of Lys255 appears to be tightly 
secured through interaction with Trp254 with little flexibility permitted. The formation of the 
hydrogen bonds suggests that the protons associated with Lys255 headgroup would face away 
from the protein surface allowing the exposure of the nitrogen atom. Moreover, the tight control 
of the position of this ε-amino group indicates that it may be a suitable site for enzyme-mediated 
nucleopohilic interactions such as ubiquitination by ubiquitin ligases. Interestingly, isomerisation 
of the phosphoSer258-Pro259 peptide bond by Pin1 (Fig 6C) renders the third carboxy group 
(Pro259) unavailable for hydrogen bond formation with Lys255 (not shown) and therefore is 
likely to cause the loss of the availability of the nitrogen atom from Lys255 for amide-
esterification, and will hamper ubiquitination.  
 
4. Discussion 
Cells are known to respond to damage and stress by releasing procoagulant microvesicles 
which may contain TF [34-37]. The release of these microvesicles from the activated cells 
complements the mechanisms that ensure the formation of an adequate clot and containment of 
the injury. However, since excessive levels of coagulation can be detrimental, it is essential that 
the cells can adjust the magnitude of their response to that of the injury. Consequently, cells need 
to detect the level of injury and gauge the amount of released TF accordingly. Moreover, once 
sufficient clot has been generated, the mechanism of TF release will have to be shut down 
rapidly. The release of TF as cell-derived microvesicles appears to be regulated through an 
ordered and time-dependent pathway which include post-transcriptional modifications of the 
cytoplasmic domain of this protein. As a result, each step permits the interaction of TF with 
components in the next step resulting in the release or endocytosis of TF. Consequently, there 
 17 
must also be factor(s) which strictly control the incorporation of TF into microvesicles and 
terminate the process once a "required amount of TF" has been released. One protein known to 
be a regulator of post-phosphorylation processes is Pin1 [15-24]. Normally peptide bond 
trans↔cis isomerisation occurs at a slow rate in nature since both of these forms are stable and 
the energy required for isomerisation is relatively high. However, the rotation of the peptide 
bond between the phosphoserine and the proline (Fig 6C) may be facilitated by enzymes 
including Pin1. Additionally, since the trans configuration is the more prevalent of the two 
isomers, Pin1 preferentially catalyses the formation of the cis isomer. The cis isomer is often not 
accessible to enzymes which bring about subsequent modifications including ubiquitination 
[19,21] and de-phosphorylation [38]. Conversely, proteins may become more accessible to such 
alternations as a consequence of isomerisation which promotes the subsequent modification. 
Therefore, Pin1 can act as a means of accelerating or delaying further processing of proteins [38] 
and has been shown to be a regulator of diverse mechanisms including cell cycle regulation 
[22,23,40-42], receptor function [42] and protein stability [16,22-24]. 
In our study, the ability of Pin1 to alter the incorporation of TF into microvesicles was clearly 
reduced in a concentration-dependent manner, through deactivation of Pin1 with Juglone but not 
its non-inhibiting analogue, Plumbagin (Fig 1). These two compounds differ by one methyl 
group and have similar activities in the cell except in the ability to deactivate Pin1 [44-46]. These 
data were also confirmed by the suppression of Pin1 expression using specific siRNA. 
Interestingly, deactivation of Pin1, or the suppression of its expression did not alter the release of 
microvesicles. This is in agreement with our previous studies which suggest that the 
incorporation of TF into microvesicles, and the process of microvesicle release, are mediated 
through distinct and separate mechanisms [4]. Although ultimately, the outcome of these two 
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mechanisms do overlap. Importantly, the ability of Pin1 to protect TF release appears to be 
through preserving the phosphorylation state of Ser253 within the cytoplasmic domain of TF 
(Fig 2). The phosphorylation of this amino acid is required for the recruitment of filamin A 
which is essential for the incorporation of TF into microvesicles [9-11]. 
Ser258→Ala-substittion of TF diminished the co-purification of Pin1 (<10%; p < 0.01) with 
mutant TF-tGFP, while Pro259→Ala-substittion of TF-tGFP was less effective (<20%; p < 0.01) 
(Fig 3A & 3B). This is in agreement with the structural analyses since the carboxy group of 
Pro259 would be needed for TF phosphorylation of Ser258 and possibly ubiquitination of 
Lys255 (see Fig. 6B). Furthermore, Pin1 preferentially interacted with Ser258-phosphorylated 
TF peptide and to a lesser extend with the double-phosphorylated peptide, but had a much lower 
affinity for the Ser253-phosphorylated peptide (Fig 3C-F). 
In addition, the inclusion of Pin1 into the in vitro phosphatase reaction, hindered the de-
phosphorylation of the double-phosphorylated TF peptide by PP2Aα, but was not as effective in 
protecting the Ser253-phosphorylated peptide (Fig 5). Together these findings suggest that 
following the phosphorylation of Ser258 within the cytoplasmic domain of TF, the formation of 
phospho-serine-proline epitope permits the interaction of Pin1 with double-phosphorylated TF. 
Since, the majority of TF is in the trans configuration, isomerisation by Pin1 favours the 
formation of the cis isomer. This form of TF is likely to be capable of interacting with filamin A 
and therefore be released, since Ser253 is located on the adjacent side of the protein [5,33] and is 
not directly affected. Moreover, the cis isomer appears to be less prone to dephosphorylation by 
PP2Aα. However, neither the trans or cis isomers of TF appeared to be ideal substrates for 
PP2Aα (Fig 5). In contrast, the rate of TF de-phosphorylation was greatly enhanced following 
ubiquitination of TF. Importantly, Pin1 was capable of effectively disrupting the ubiquitination 
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of TF peptide by the ubiquitin ligase complex (Fig 4C) as well as the dephosphorylation of the 
ubiquitinated peptide (5C). This was further supported by the suppression of Pin1 expression 
which resulted in accelerated ubiquitination of TF in cells (Fig 4B). Together, these observations 
suggest that the main mode of action of Pin1 is through the prevention of ubiquitination of the 
cytoplasmic domain of TF, which is essential for the rapid de-phosphorylation of Ser253 within 
TF, by PP2Aα (Fig 7). Consequently, it is possible that the cis isomer of TF may be incorporated 
and released into microvesicles unhindered. This is not in agreement with our previous report 
which indicated that endothelial-derived microvesicles do not contain double-phosphorylated TF 
[4]. Nonetheless, the concentration of Pin1 within normal primary cells was determined to be in 
the range of 19 nM. Therefore, it is likely that depending on the amount of TF being released, 
arising from the level of injury/trauma, cellular Pin1 may become saturated. As a result, a small 
amount of TF may become ubiquitinated, de-phosphorylated and possibly endocytosed [6]. Since 
Ser258-phosphorylated TF appears to be the preferred substrate for Pin1 (Fig 3), the 
sequestration of Pin1 to Ser258-phosphorylated TF further reduces the amount of available Pin1 
(Fig 7). Consequently, the reduction in the rate of isomerisation of double-phosphorylated TF 
would lead to the progressively accelerated TF ubiquitination and the abrupt termination of TF 
release. Therefore at least in normal cells, the majority of TF will be released in the Ser253-
phposphorylated form and only a minor amount will be released in the double-phosphorylated 
form. This explains the lack of detectable phosphorylated Ser258 in endothelial cells as reported 
in our previous study [4]. Furthermore, it is interesting to note that tumour cells such as MDA-
MB-231 cells often contain much higher levels of Pin1 (44.8 nM) which may reach 
concentrations of up to 500 nM in some cancer cells [39,47-49]. This explains how these cells 
retain their ability to release TF at high rates even in the presence of augmented expression levels 
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of TF. In addition, ubiquitinated receptors are often endocytosed through ubiquitin-dependent 
receptors [49-53] which explains how the mechanism of termination is effective in rodents, 
without the need for dephosphorylation of a serine residue which lacks in murine. 
The regulation of incorporation and release of TF within cell-derived microvesicles appears 
to involve Pin1 as a means by which cells gauge the level of TF required and released for 
appropriate coagulation. Although there are some difference in the induction of TF 
activation/release, the general mechanisms of the incorporation into microvesicles appear to have 
much in common. As examples, ATP [54] and PAR2-dpendent [9] activation both appear to 
involve the cytoskeletal protein filamin A as an essential component if TF incorporation into the 
microvesicles. In fact, we recently have shown that the interaction of filamin A is particularly 
dependent on the phosphorylation of Ser253 within TF alone and this common mechanism 
occurs following the activation of cells with either PAR2-agonist or FVIIa [55]. We envisage 
that our model of PAR2-induced microvesicle release may occur a) by vascular cells in response 
to local activation of the coagulation mechanisms amplifying the response, and also b) as a 
consequence of exposure of TF-carrying cancer cells to the bloodstream [56] and may be 
precursor to tumour-induced thrombosis shown using in vivo models [57]. In fact, we have 
previously shown that TF-containing microvesicles are capable of interacting with extracellular 
matrices, fibronectin and collagen [28]. Therefore, it is likely that although various types of cells 
may respond to different agonist, through diverse signalling pathways that converge and 
culminate in common mechanisms of TF release that play an active role in 
coagulation/thrombosis. However, these initial signalling pathways may also be the determinants 
for the incorporation of other receptors, proteins and molecules which instruct the behaviour of 
the microvesicles and the cells/tissue that they interact with. 
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In conclusion, Pin1 is a fast acting enzyme capable of interacting with the cytoplasmic 
domain of TF and protecting this protein from ubiquitination and the subsequent 
dephosphorylation. Therefore, Pin1 acts as a gauge for the amount of TF being released by the 
cells and therefore functions to determine the level of injury incurred. 
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Figure Legends 
Table 1. Relative dissociation constants for the interactions of Pin1 with TF-peptide interaction. 
The substrate peptide corresponding to the last 19 amino acids of the cytoplasmic domain of TF 
were synthesised in biotinylated form as non-phosphorylated, single-phosphorylated and double-
phosphorylated forms. The peptides (5 µM final concentration) were adsorbed onto 
NeutrAvidin-coated 96-well plate and the wells were washed. The samples were incubated with 
HRP-conjugated recombinant Pin1 protein diluted in PBST (0-20 nM) and added to wells (100 
µl) and incubated for 1 h at room temperature. The wells were then washed a further four times 
and developed with TMB One Solution (100 µl) and the absorptions measured at 450 nm using a 
plate reader. The relative dissociation constant values were calculated from the curves and the 
dissociation constants expressed in terms of Pin1 concentration. 
 
Table 2. Analysis of the interaction of Lys255 with surrounding amino acid groups. The 10 
NMR structure of the cytoplasmic domain of TF were obtained from the databank (2CEF) and 
the distance between the nitrogen of the ε-amino group within Lys255 and the oxygen within the 
carboxy groups of Glu256, Asn257, PhosphsSer258 and Pro259 were examined. The percentage 
of incidence, where the two atoms were proximal was determined for each set of amino acid 
within the 10 structures. In addition, the average distances between the nitrogen of the ε-amino 
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group within Lys255, and the oxygen within the carboxy groups of respective amino was also 
calculated. 
 
Fig. 1 The influence of Pin1 on the release of TF within microvesicles. MDA-MB-231 cells and 
transfected HCAEC expressing TF-tGFP (2×105) were pre-adapted to serum-free medium and 
pre-incubated with Juglone (0-60 nM) or Plumbagin (0-60 nM) for for 60 min. The cells were 
then activated with PAR2-AP (20 µM) and microvesicles were isolated from the conditioned 
media of the cells at 30 and 90 min post-activations, respectively. The concentration of TF in A) 
MDA-MB-231 cells and B) HCAEC was determined using a TF-EIA and differences were 
assessed by ANOVA (n = 3; * = p<0.05 & ** = p<0.01 vs the vehicle control sample without 
any reagent). Microvesicle densities were also determined in C) MDA-MB-231 cells and D) 
HCAEC using the Zymuphen microparticle assay kit and differences were assessed by ANOVA. 
(n = 4; ** = p<0.01 vs the non-activated sample). MDA-MB-231 cells with a specific siRNA to 
suppress Pin1 expression or a control siRNA prior and incubated for 48 h. HCAEC (2×105) were 
also co-transfected to express TF-tGFP, together with siRNA to suppress Pin1 expression or a 
control siRNA, and incubated for 48 h. The cells were then pre-adapted to serum-free medium 
and activated with PAR2-AP (20 µM). Microvesicles were isolated from the conditioned media 
of the cells and the concentration of TF in E) MDA-MB-231 cells and F) HCAEC was 
determined using a TF-EIA and differences were assessed by ANOVA (n = 4; ** = p<0.01 vs 
the non-activated sample # = p<0.01 vs the control siRNA sample). Microvesicle densities were 
also determined in G) MDA-MB-231 cells and H) HCAEC using the Zymuphen microparticle 
assay kit and differences were assessed by ANOVA (n = 4; ** = p<0.01 vs the non-activated 
sample). 
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Fig. 2 The influence of Pin1 on TF phosphorylation at Ser253 and Ser258. MDA-MB-231 cells 
(2×105) were transfected with a specific siRNA to suppress Pin1 expression or a confirmed 
control siRNA prior and incubated for 48 h. The cells were pre-adapted to serum-free medium 
and then activated with PAR2-AP (20 µM). Cells were lysed in phosphosafe buffer and the TF 
was immunoprecipitated using a mouse anti-human TF antibody (10H10; 4 µg) and captured 
using protein A-magnetic beads. The precipitate was washed four times with PBST and briefly 
boiled in electrophoresis loading buffer and separated by electrophoresis on a denaturing 12% 
(w/v) polyacrylamide gel. The proteins were then transferred to a nitrocellulose membrane and 
blocked. A) TF phosphorylation at Ser258 was detected using a rabbit anti-phosphoserine-TF 
antibody specific for phospho-Ser258, diluted 1:2000 (v/v) in TBST while phosphorylation of 
Ser253 was detected using a rabbit anti-phospho-PKC-substrate motif antibody diluted 1:2000 
(v/v) in TBST buffer. Total TF protein was also detected alongside using a rabbit anti-human TF 
antibody (FL295) diluted 1:2000 (v/v). After washes with TBST all membranes were developed 
with goat anti-rabbit alkaline phosphatase-conjugated antibody diluted 1:4000 (v/v) and then 
visualised using the Western Blue stabilised alkaline phosphatase-substrate and recorded (the 
micrographs are representative of 3 experiments). B) The band densities of the phosphorylated 
TF were measured at 15, 30 and 45 min post-activation using the ImageJ programme and 
calculated as a ratio of total TF protein for B) Ser253-phosphorylated TF and C) Ser258-
phosphorylated TF. Differences were assessed by ANOVA (n = 4; * = p<0.05 vs the respective 
non-activated sample). 
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Fig. 3 Analysis of the interaction of recombinant Pin1 with TF-derived peptides. Cells were 
transfected to overexpress wild-type TF-tGFP or alternatively mutants with substitutions at 
Ser258 or Pro259. TF-tGFP was immunoprecipitated using anti-tGFP-magnetic beads (clone 
2H8) (25 μl). In some samples, TF protein was immunoprecipitated from cell lysates using a 
rabbit anti-human antibody (FL295) (4 µg per sample) and then purified using Pureproteome 
protein A-magnetic beads. A) The purified samples were separately probed with a rabbit anti-
Pin1 polyclonal antibody, TF (10H10) and tGFP (2H8) by western blot analysis. B) The intensity 
of the bands were measured and the amount of the co-immunoprecipitated Pin1 was quantified 
by determining the intensity of Pin1 bands as a ratio the intensity of tGFP. Differences were 
assessed by ANOVA (n = 3; * = p<0.01 vs the wild-type TF-tGFP sample/immunoprecipitated 
with 2H8 antibody). C) The substrate peptide corresponding to the last 19 amino acids of the 
cytoplasmic domain of TF were synthesised as biotin conjugates, in non-phosphorylated, single-
phosphorylated and double-phosphorylated forms. A scrambled peptide was also included. The 
peptides (5 µM final concentration) were diluted to 100 µl with PBS and distributed (50 µl per 
well) in a NeutrAvidin-coated 96-well plate and incubated for 2 h at room temperature. The 
wells were washed four times with PBST (300 µl). HRP-conjugated recombinant Pin1 protein 
was diluted in PBST (2 nM) and added to wells (100 µl) and incubated for 1 h at room 
temperature. The wells were then washed a further four times and developed with TMB One 
Solution (100 µl). The reactions were terminated by the addition of 2M sulphuric acid (50 µl) 
and absorptions measured at 450 nm using a plate reader. Differences were assessed by ANOVA 
(n = 5; * = p<0.05 vs the scrambled peptide). D) The procedure was repeated out in triplicate at a 
range of Pin1 concentrations (0-20 nM) and the absorptions recorded at each concentration. E) 
The Pin1-binding experiment was also repeated as above but by subsituting recombinant Pin1 
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with cell lysate. The samples were then probed with and HRP-conjugated anti-Pin1 antibody, 
washed and developed with TMB One Solution (100 µl). The recordings were obtained as above 
and differences were assessed by ANOVA (n = 3; * = p<0.05 vs the scrambled peptide). F) 
Samples of the affinity-purified Pin1 from C were dissolved in the electrophoresis loading buffer 
and analysed by western blot. The samples were probed using a rabbit anti-human Pin1 
polyclonal antibody diluted 1:2000 (v/v) in TBST. The membranes were then washed with TBST 
and probed with goat anti-rabbit alkaline phosphatase-conjugated antibody diluted 1:4000 (v/v) 
and incubated for 90 min. Pin1 bands were then visualised using the Western Blue stabilised 
alkaline phosphatase-substrate and recorded (the micrographs are representative of 3 
experiments). G) Labeled penta-peptide Succ-Glu-Asn-Ser-Pro-Leu-pNitroanilide and Succ-Glu-
Asn-phosphoSer-Pro-Leu-pNitroanilide were synthesisd and reconstituted (0.5 µM) in Tris-HCl 
buffer at a range of pH values (5.5-9.5). The absorption spectra of the peptide was analysed at 
260-360 nm range and the maximal change in the absorption spectrum was determined. The 
wavelength with the maximal absorption change was determined to be 315 nm. H) Samples (100 
µl) of the peptides were in turn placed in a microcuvette, and recombinant HRP-conjugated Pin1 
added (10 nM final concentration). The change in absorption at 315 nm over time was then 
monitored. (n = 5). 
 
Fig. 4 The influence of Pin1 on TF ubiquitination. MDA-MB-231 cells (2×105) were transfected 
with a specific siRNA to suppress Pin1 expression or a confirmed control siRNA prior and 
incubated for 48 h. The cells were then pre-adapted to serum-free medium and activated with 
PAR2-AP (20 µM). Cells were harvested at 15 and 30 min post-activation and lysed in 
phosphosafe buffer and the TF was immunoprecipitated using a rabbit anti-human TF antibody 
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(FL295; 4 µg) and captured using protein A-magnetic beads. The precipitate was washed four 
times with PBST and briefly boiled in electrophoresis loading buffer and separated by 
electrophoresis on a denaturing 12% (w/v) polyacrylamide gel. The proteins were then 
transferred to a nitrocellulose membrane and blocked. A) TF ubiquitination was detected using a 
mouse anti-human mono/poly-ubiquitin (FK2) antibody diluted 1:4000 (v/v). Total TF protein 
was detected using a mouse anti-human TF antibody (10H10) diluted 1:2000 (v/v). The 
membranes were then washed with TBST and probed with goat anti-mouse alkaline 
phosphatase-conjugated antibodies diluted 1:4000 (v/v) and TF bands were visualised using the 
Western Blue stabilised alkaline phosphatase-substrate and recorded (the micrographs are 
representative of 3 experiments). B) The ubiquitinated TF band densities were measured at 15, 
30 and 45 min post-activation, using the ImageJ programme and determined as a ratio of the total 
TF protein bands. Differences were assessed by ANOVA (n = 5; * = p<0.05 vs the non-activated 
sample). C) Ubiquitination reaction was carried out in the presence of a range of concentrations 
of Pin1 (0-10 nM). The reaction was prepared to contain the double-phosphorylated TF peptide 
as substrate (5 µM), Ube1 enzyme (0.1 µM), an equal mix of Ube2D enzyme mix (2 µM), 
ubiquitin monomer (50 µM), ATP (2 mM), glycerol (5% w/v) and reaction buffer (20 mM Tris, 
pH 7.6, 50 mM NaCl, 1 mM β-mercapthoethanol and 5 mM MgCl2) and recombinant Mdm2 (0.5 
µM). The reactions were carried out at 37°C for 60 min and then diluted to 100 µl with PBS and 
distributed (50 µl per well) in a NeutrAvidin-coated 96-well plate and incubated for 1 h at room 
temperature. The wells were washed four times, each time with 300 µl of PBST and incubated 
with HRP-conjugated anti-human mono/poly-ubiquitin (FK2) antibody diluted 1:500 (v/v) in 
PBST. The wells were then washed a further four times and developed with TMB One Solution 
(100 µl). Once the colour was developed the reactions were stopped by the addition of 2M 
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sulphuric acid (50 µl) and absorptions measured at 450 nm using a plate reader. Differences were 
assessed by ANOVA (n = 5; * = p<0.05 vs the sample without any Pin1). 
 
Fig. 5 The influence of Pin1 on TF dephosphorylation by PP2A. Three sets of TF peptides A) 
Ser253-phosphorylated, B) double-phosphorylated and C) ubiquitinated-double-phosphorylated 
(10 µM) were pre-adsorbed onto the NeutrAvidin 96-well plates and washed fours times with 
phosphate-free Tris-HCl (50 mM) pH 7.5 (300 µl). Pin1 (1-10 nM) was added to each set of the 
samples Each reaction (25 µl) was prepared by reconstituting recombinant phosphatase PP2Aα 
(0.2 µg) in phosphatase reaction buffer (200 mM immidazole pH 7.2, 0.1% (w/v) β-
mercapthoethanol and 52 ng/ml bovine serum albumin) and MgCl2 (10 mM). A positive control 
was prepared as above but containing the peptide KRpTIRR (10 µM) as the recommended 
control substrate by the phosphatase PP2A manufacturer. A negative control devoid of substrate 
was also included. The samples were incubated at 37°C for 60 min and aliquots of reaction (20 
µl) were transferred into a fresh 96-well plate and 150 µl of BioMol added and incubated for 30 
min. The absorptions were then measured at 630 nm using a plate reader and concentrations 
determined from a phosphate-standard curve. Differences were assessed by ANOVA (n = 5; * = 
p<0.05 vs the sample without any PP2A; # = p<0.05 vs the postive control). 
 
Fig. 6 Structural representation of the cytoplasmic domain of TF and the trans and cis forms of 
phosphoserine-proline motif. A) Molecular surface model of the cytoplasmic domain of TF 
(amino acids 247-263) depicting the position of Lys255 (blue) on the surface, Trp254 (brown) 
and the carboxy groups of Asn257, pSer258 and Pro259 (red) as well as the phospho group of 
Se258 (yellow + red). B) stick model of the cytoplasmic domain of TF (amino acids 252-259) 
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showing the interaction of the head group of Lys255 (blue) with the carboxyl groups of Asn257, 
pSer258 and Pro259 (red). C) The phosphoserine-proline motif exists in two configurations. The 
energetically unfavourable isomerisation is catalysed by Pin1 through the rotation of peptide 
bond (round arrow). The isomerisation alters the direction of the peptide (straight arrows) 
altering the accessible motifs/domains. 
 
Fig. 7 Proposed mechanism of the regulation of TF release by Pin1. The phosphorylation of the 
cytoplasmic domain of TF permits its interaction with filamin A and release within 
microvesicles. Protein isomerisation by Pin1 (A), allows further TF release (B) by preventing the 
ubiquitination of Lys255 (C) and the subsequent dephosphorylation of Ser253 (D). However, the 
eventual ubiquitination and dephosphorylation of TF at Ser253 sequesters Pin1 away to the more 
favourable substrate (Ser258-phosphorylated) resulting the progressively accelerated TF 
ubiquitination and dephosphorylation (C & D) and termination of TF release. 
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Table 1 
 
Peptide Relative Kd (nM) 
Unphosphorylated TF peptide 3.25 
Ser253-phosphorylated peptide 3.62 
Ser258-phosphorylated peptide 0.79 
Double-phosphorylated peptide 1.53 
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Table 2 
 
Amino acid Number of incidence Average distance (Å) 
Glu256 60% 4.20 ± 0.91 
Asn257 80% 3.88 ± 0.95 
phospho-Ser258 100% 2.90 ± 0.14 
Pro259 70% 3.99 ± 0.64 
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Figure 5 
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Figure 6 
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Figure 7 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
